The road to resistance: EGFR mutation and cetuximab

被引：58

作者：

Bardelli, Alberto ^{[1
]}

Jaenne, Pasi A. ^{[2
]}

机构：

[1] Univ Turin, Mol Genet Lab, Inst Canc Res & Treatment, Sch Med, Turin, Italy

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

NATURE MEDICINE | 2012年 / 18卷 / 02期

关键词：

ACQUIRED-RESISTANCE; PANITUMUMAB;

D O I：

10.1038/nm.2646

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

引用

页码：199 / 200

页数：2

共 14 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer [J].

Bardelli, Alberto ;

Siena, Salvatore .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1254-1261

[3] Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells [J].

Benavente, Sergio ;

Huang, Shyhmin ;

Armstrong, Eric A. ;

Chi, Alexander ;

Hsu, Kun-Tai ;

Wheeler, Deric L. ;

Harari, Paul M. .

CLINICAL CANCER RESEARCH, 2009, 15 (05) :1585-1592

[4] A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer [J].

Bertotti, Andrea ;

Migliardi, Giorgia ;

Galimi, Francesco ;

Sassi, Francesco ;

Torti, Davide ;

Isella, Claudio ;

Cora, Davide ;

Di Nicolantonio, Federica ;

Buscarino, Michela ;

Petti, Consalvo ;

Ribero, Dario ;

Russolillo, Nadia ;

Muratore, Andrea ;

Massucco, Paolo ;

Pisacane, Alberto ;

Molinaro, Luca ;

Valtorta, Emanuele ;

Sartore-Bianchi, Andrea ;

Risio, Mauro ;

Capussotti, Lorenzo ;

Gambacorta, Marcello ;

Siena, Salvatore ;

Medico, Enzo ;

Sapino, Anna ;

Marsoni, Silvia ;

Comoglio, Paolo M. ;

Bardelli, Alberto ;

Trusolino, Livio .

CANCER DISCOVERY, 2011, 1 (06) :508-523

[5] Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].

De Roock, Wendy ;

Claes, Bart ;

Bernasconi, David ;

De Schutter, Jef ;

Biesmans, Bart ;

Fountzilas, George ;

Kalogeras, Konstantine T. ;

Kotoula, Vassiliki ;

Papamichael, Demetris ;

Laurent-Puig, Pierre ;

Penault-Llorca, Frederique ;

Rougier, Philippe ;

Vincenzi, Bruno ;

Santini, Daniele ;

Tonini, Giuseppe ;

Cappuzzo, Federico ;

Frattini, Milo ;

Molinari, Francesca ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Martini, Miriam ;

Bardelli, Alberto ;

Siena, Salvatore ;

Sartore-Bianchi, Andrea ;

Tabernero, Josep ;

Macarulla, Teresa ;

Di Fiore, Frederic ;

Gangloff, Alice Oden ;

Ciardiello, Fortunato ;

Pfeiffer, Per ;

Qvortrup, Camilla ;

Hansen, Tine Plato ;

Van Cutsem, Eric ;

Piessevaux, Hubert ;

Lambrechts, Diether ;

Delorenzi, Mauro ;

Tejpar, Sabine .

LANCET ONCOLOGY, 2010, 11 (08) :753-762

[6] Factors underlying sensitivity of cancers to small-molecule kinase inhibitors [J].

Jaenne, Pasi A. ;

Gray, Nathanael ;

Settleman, Jeff .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (09) :709-723

[7] Cetuximab for the treatment of colorectal cancer [J].

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Karapetis, Christos S. ;

Zalcberg, John R. ;

Tu, Dongsheng ;

Au, Heather-Jane ;

Berry, Scott R. ;

Krahn, Marianne ;

Price, Timothy ;

Simes, R. John ;

Tebbutt, Niall C. ;

van Hazel, Guy ;

Wierzbicki, Rafal ;

Langer, Christiane ;

Moore, Malcolm J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048

[8] K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].

Karapetis, Christos S. ;

Khambata-Ford, Shirin ;

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Tu, Dongsheng ;

Tebbutt, Niall C. ;

Simes, R. John ;

Chalchal, Haji ;

Shapiro, Jeremy D. ;

Robitaille, Sonia ;

Price, Timothy J. ;

Shepherd, Lois ;

Au, Heather-Jane ;

Langer, Christiane ;

Moore, Malcolm J. ;

Zalcberg, John R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765

[9] Nuclear EGFR contributes to acquired resistance to cetuximab [J].

Li, C. ;

Iida, M. ;

Dunn, E. F. ;

Ghia, A. J. ;

Wheeler, D. L. .

ONCOGENE, 2009, 28 (43) :3801-3813

[10] Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the Anti-EGFR monoclonal antibody cetuximab [J].

Lu, Yang ;

Li, Xinqun ;

Liang, Ke ;

Luwor, Rodney ;

Siddik, Zahid H. ;

Nuiis, Gordon B. ;

Mendelsohn, John ;

Fan, Zhen .

CANCER RESEARCH, 2007, 67 (17) :8240-8247

← 1 2 →